New developments in ureteral stent design, materials and coatings

Expert Review of Medical Devices

Volumn 3, Issue 3, 2006, Pages 395-403

  Chew, Ben H ^a   Duvdevani, Mordechai ^b   Denstedt, John D ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Biofilm; Biomaterial; Drug eluting; Encrustation; Nephrolithiasis; Stent; Ureter; Urinary tract infection

Indexed keywords

ANALGESIC AGENT; BIOMATERIAL; CHOLINERGIC RECEPTOR BLOCKING AGENT; HEPARIN; KETOROLAC; LIDOCAINE; OXYBUTYNIN; PHOSPHORYLCHOLINE; POLYURETHAN; SODIUM CHLORIDE; TRICLOSAN;

BIODEGRADATION; BIOFILM; CLINICAL TRIAL; DRUG ELUTING STENT; HUMAN; HYDROGEL; INFECTION RISK; MORBIDITY; NONHUMAN; PH; REVIEW; SYMPTOM; TISSUE ENGINEERING; TREATMENT INDICATION; URETER STENT; URINARY TRACT DISEASE; URINARY TRACT INFECTION;

COATED MATERIALS, BIOCOMPATIBLE; EQUIPMENT DESIGN; HUMANS; PROSTHESIS-RELATED INFECTIONS; STENTS; URETERAL DISEASES; URINARY CATHETERIZATION; URINARY TRACT INFECTIONS;

EID: 33646581683     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/17434440.3.3.395     Document Type: Review

References (78)

1. Bloom DA, Clayman RV, McDougal E. Stents and related terms: a brief history. Urulogy 54(4), 767-771 (1999).
2. Finney RP. Experience with new double J ureteral catheter stent. J. Urol. 120(6), 678-681 (1978).
3. Joshi HB, Okeke A, Newns N, Keeley FX Jr, Timoney AG. Characterization of urinary symptoms in patients with ureteral stents. Urology 59(4), 511-516 (2002).
4. El-Nahas AR, El-Assmy AM, Shoma AM, Eraky I, El-Kenawy MR, El-Kappany HA. Self-retaining ureteral stents: analysis of factors responsible for patients' discomfort. J. Endourol. 20(1), 33-37 (2006).
5. Joshi HB, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG, Barry MJ. Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J. Urol. 169(3), 1065-1069 (2003).
6. Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG. Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J. Urol. 169(3), 1060-1064 (2003).
7. Damiano R, Oliva A, Esposito C, De Sio M, Autorino R, D'Armiento M. Early and late complications of double pigtail ureteral stent. Urol. Int. 69(2), 136-140 (2002).
8. Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG. The development and validation of a patient-information booklet on ureteric stents. BJU Int. 88(4), 329-334 (2001).
9. Hosking DH, McColm SE, Smith WE. Is stenting following ureteroscopy for removal of distal ureteral calculi necessary? J. Urol. 161(1), 48-50 (1999).
10. Denstedt JD, Wollin TA, Sofer M, Nott L, Weir M, D'A HR. A prospective randomized controlled trial comparing nonstented versus stented ureteroscopic lithotripsy. J. Urol. 165(5), 1419-1422 (2001).
11. Byrne RR, Auge BK, Kourambas J, Munver R, Delvecchio F, Preminger GM. Routine ureteral stenting is not necessary after ureteroscopy and ureteropyeloscopy: a randomized trial. J. Endourol. 16(1), 9-13 (2002).
12. Chen YT, Chen J, Wong WY, Yang SS, Hsieh CH, Wang CC. Is ureteral stenting necessary after uncomplicated ureteroscopic lithotripsy? A prospective, randomized controlled trial. J. Urol. 167(5), 1977-1980 (2002).
13. Hollenbeck BK, Schuster TG, Faerber GJ, Wolf JS Jr. Routine placement of ureteral stents is unnecessary after ureteroscopy for urinary calculi. Urology 57(4), 639-643 (2001).
14. Hollenbeck BK, Schuster TG, Seifman BD, Faerber GJ, Wolf JS Jr. Identifying patients who are suitable for stentless ureteroscopy following treatment of urolithiasis. J. Urol. 170(1), 103-106 (2003).
15. Mardis HK, Kroeger RM. Ureteral stents. Materials. Urol. Clin. North Am. 15(3), 471-479 (1988).
16. Tieszer C, Reid G, Denstedt J. Conditioning film deposition on ureteral stents after implantation. J. Urol. 160(3 Pt 1), 876-881 (1998).
17. Riedl CR, Plas E, Hubner WA, Zimmerl H, Ulrich W, Pfluger H. Bacterial colonization of ureteral stents. Eur. Urol. 36(1), 53-59 (1999).
18. Paick SH, Park HK, Oh SJ, Kim HH. Characteristics of bacterial colonization and urinary tract infection after indwelling of double-J ureteral stent. Urology 62(2), 214-217 (2003).
19. Reid G, Habash M, Vachon D, Denstedt J, Riddell J, Beheshti M. Oral fluoroquinolone therapy results in drug adsorption on ureteral stents and prevention of biofilm formation. Int. J. Andmicrob. Agents 17(4), 317-319 (2001).
20. Wollin TA, Tieszer C, Riddell JV, Denstedt JD, Reid G. Bacterial biofilm formation, encrustation, and antibiotic adsorption to ureteral stents indwelling in humans. J. Endourol. 12(2), 101-111 (1998).
21. Kehinde EO, Rotimi VO, Al-Hunayan A, Abdul-Halim H, Boland F, Al-Awadi KA. Bacteriology of urinary tract infection associated with indwelling J ureteral stents. J. Endourol. 18(9), 891-896 (2004).
22. Singh I, Gupta NP, Hemal AK, Aron M, Seth A, Dogra PN. Severely encrusted polyurethane ureteral stents: management and analysis of potential risk factors. Urology 58(4), 526-531 (2001).
23. el Faqih SR, Shamsuddin AB, Chakrabarti A et al. Polyurethane internal ureteral stents in treatment of stone patients: morbidity related to indwelling times. J. Urol. 146(6), 1487-1491 (1991).
24. Singh V, Srinivastava A, Kapoor R, Kumar A. Can the complicated forgotten indwelling ureteric stents be lethal? Int. Urol. Nephrol. 37(3), 541-546 (2005).
25. Monga M, Klein E, Castaneda-Zuniga WR, Thomas R. The forgotten indwelling ureteral stent: a urological dilemma. J. Urol. 153(6), 1817-1819 (1995).
26. Bultitude ME, Dasgupta P, Cynk M, Glass JM, Tiptaft RC. Lower ureteric obstruction: a complication of tailed ureteric stents. BJU Int. 91(6), 581 (2003).
27. Dunn MD, Portis AJ, Kahn SA et al. Clinical effectiveness of new stent design: randomized single-blind comparison of tail and double-pigtail stents. J. Endourol. 14(2), 195-202 (2000).
28. Liatsikos EN, Hom D, Dinlenc, CZ et al. Tail stent versus re-entry tube: a randomized comparison after percutaneous stone extraction. Urology 59(1), 15-19 (2002).
29. Yew J, Bellman G. Modified 'tubeless' percutaneous nephrolithotomy using a tailstent. Urology 62(2), 346-349 (2003).
30. Gerber R, Nitz C, Studer UE, Danuser H. Spiral stent versus standard stent in patients with midsize renal stones treated with extracorporeal shock wave lithotripsy: which stent works better? A prospective randomized trial. J. Urol, 172(3), 965-966 (2004).
31. Stoller ML, Schwartz BF, Frigstad JR, Norris L, Park JB, Magliochetti MJ. An in vitro assessment of the flow characteristics of spiral-ridged and smooth-walled JJ ureteric stents. BJU Int. 85(6), 628-631 (2000).
32. Olweny EO, Landman J, Andreorri C et al. Evaluation of the use of a biodegradable ureteral stent after retrograde endopyelotomy in a porcine model. J. Urol. 167(5), 2198-2202 (2002).
33. Lingeman JE, Preminger GM, Berger Y et al. Use of a temporary ureteral drainage stent after uncomplicated ureteroscopy: results from a phase II clinical trial. J. Urol. 169(5), 1682-1688 (2003).
34. Auge BK, Ferraro RF, Madenjian AR, Preminger GM. Evaluation of a dissolvable ureteral drainage stent in a Swine model. J. Urol. 168(2), 808-812 (2002).
35. Taylor WN, McDougall IT. Minimally invasive ureteral stent retrieval. J. Urol. 168(5), 2020-2023 (2002).
36. Ilker Y, Turkeri L, Dillioglugil O, Akdas A. Spontaneous fracture of indwelling ureteral stents in patients treated with extracorporeal shock wave lithotripsy: two case reports. Int. Urol. Nephrol. 28(1), 15-19 (1996).
37. Buchholz NN, Cannaby C, Fong R, Gray A, Andrews HO, Birch MJ. A new SWL titanium stent (Zebra Stent): resistance to shockwave exposure. J. Endourol. 19(5), 584-588 (2005).
38. Moskovitz B, Vardi Y, Wislang M, Levin DR. Fracture of double-J ureteric stents: a report of two cases. Urol. Int. 44(4), 241-243 (1989).
39. Gorman SP, Tunney MM, Keane PF, Van Bladel K, Bley B. Characterization and assessment of a novel poly(ethylene oxide)/polyurethane composite hydrogel (Aquavene) as a ureteral stent biomaterial. J. Biomed. Mater. Res. 39(4), 642-649 (1998).
40. Park JH, Cho YW, Kwon IC, Jeong SY, Bae YH. Assessment of PEO/PTMO multiblock copolymer/segmented polyurethane blends as coating materials for urinary catheters: in vitro bacterial adhesion and encrustation behavior. Biomaterials 23(19), 3991-4000 (2002).
41. Watterson JD, Cadieux PA, Stickler D, Reid G, Denstedt JD. Swarming of Proteus mirabilis over ureteral stents: a comparative assessment. J. Endourol. 17(7), 523-527 (2003).
42. Tunney MM, Keane PF, Gorman SP. Assessment of urinary tract biomaterial encrustation using a modified Robbins device continuous flow model. J. Biomed. Mater. Res. 38(2), 87-93 (1997).
43. Jones DS, Garvin CP, Gorman SP. Relationship between biomedical catheter surface properties and lubricity as determined using textural analysis and multiple regression analysis. Biomaterials 25(7-8), 1421-1428 (2004).
44. Marx M, Bettmann MA, Bridge S, Brodsky G, Boxt LM, Richie JP. The effects of various indwelling ureteral catheter materials on the normal canine ureter. J. Urol. 139(1), 180-185 (1988).
45. Joshi HB, Chitale SV, Nagarajan M et al. A prospective randomized single-blind comparison of ureteral stents composed of firm and soft polymer. J. Urol. 114(6), 2303-2306 (2005).
46. Isotalo T, Talja M, Valimaa T, Tormala P, Tammela TL. A bioabsorbable self-expandable, self-reinforced poly-L-lactic acid urethral stent for recurrent urethral strictures: long-term results. J. Endourol. 16(10), 759-762 (2002).
47. Laaksovirta S, Isotalo T, Talja M, Valimaa T, Tormala P, Tammela TL. Interstitial laser coagulation and biodegradable self-expandable, self-reinforced poly-L-lactic and poly-L-glycolic copolymer spiral stent in the treatment of benign prostatic enlargement. J. Endourol. 16(5), 311-315 (2002).
48. Choong SK, Hallson P, Whitfield HN, Fry CH. The physicochemical basis of urinary catheter encrustation. BJU Int. 83(7), 770-775 (1999).
49. Chitale SV, Scott-Barrett S, Ho ET, Burgess NA. The management of ureteric obstruction secondary to malignant pelvic disease. Clin. Radial. 57(12), 1118-1121 (2002).
50. Pauer W, Lugmayr H. Metallic wallstents: a new therapy for extrinsic ureteral obstruction. J. Urol. 148 (2 Pt 1), 281-284 (1992).
51. Kulkarni R, Bellamy E. Nickel-titanium shape memory alloy Memokath 051 ureteral stent for managing long-term ureteral obstruction: 4-year experience. J. Urol. 166(5), 1750-1754 (2001).
52. Daskalopoulos G, Hatzidakis A, Triantafyllou T et al. Intraureteral metallic endoprosthesis in the treatment of ureteral strictures. Eur. J. Radiol. 39(3), 194-200 (2001).
53. Barbalias GA, Liatsikos EN, Kalogeropoulou C et al. Externally coated ureteral metallic stents: an unfavorable clinical experience. Eur. Urol. 42(3), 276-280 (2002).
54. Amiel GE, Yoo JJ, Kim BS, Atala A. Tissue engineered stents created from chondrocytes. J. Urol. 165(6 Pt 1), 2091-2095 (2001).
55. Smith TG III, Gettman M, Lindberg G, Napper C, Pearle MS, Cadeddu JA. Ureteral replacement using porcine small intestine submucosa in a porcine model. Urology 60(5), 931-934 (2002).
56. Landman J, Olweny E, Sundaram CP et al. Laparoscopic mid sagittal hemicystectomy and bladder reconstruction with small intestinal submucosa and reimplantation of ureter into small intestinal submucosa: 1-year follow-up. J. Urol. 171(6 Pt 1), 2450-2455 (2004).
57. Desgrandchamps F, Moulinier F, Daudon M, Teillac P, Le Duc A. An in vitro comparison of urease-induced encrustation of JJ stents in human urine. Br. J. Urol. 79(1), 24-27 (1997).
58. Tunney MM, Gorman SP. Evaluation of a poly(vinyl pyrollidone)-coated biomaterial for urological use. Biomaterials 23(23), 4601-4608 (2002).
59. Riedl CR, Witkowski M, Plas E, Pflueger H. Heparin coating reduces encrustation of ureteral stents: a preliminary report. Int. J. Antimicrob. Agents 19(6), 507-510 (2002).
60. Tenke P, Riedl CR, Jones GL, Williams GJ, Stickler D, Nagy E. Bacterial biofilm formation on urologic devices and heparin coating as preventive strategy. Int. J. Antimicrub. Agents 23 (Suppl. 1), S67-S74 (2004).
61. Multanen M, Tammela TL, Laurila M et al. Biocompatibility, encrustation and biodegradation of ofloxacine and silver nitrate coated poly-L-lactic acid stents in rabbit urethra. Urol. Res. 30(4), 227-232 (2002).
62. Stickler DJ. Biomaterials to prevent nosocomial infections: is silver the gold standard? Curr. Opin. Infect. Djs. 13(4), 389-393 (2000).
63. Stickler DJ, Evans A, Morris N, Hughes G. Strategies for the control of catheter encrustation. Int. J. Andmicrob. Agents 19(6), 499-506 (2002).
64. Airoldi F, Di MC, Ribichini F et al. 17-beta-estradiol eluting stent versus phosphorylcholine-coated stent for the treatment of native coronary artery disease. Am. J. Cardiol. 96(5), 664-667 (2005).
65. Bakhai A, Booth J, Delahunty N et al. The SV stent study: a prospective, multicentre, angiographic evaluation of the BiodivYsio phosphorylcholine coated small vessel stent in small coronary vessels. Int. J. Cardiol, 102(1), 95-102 (2005).
66. Lowe R, Menown IB, Nogareda G, Penn IM. Coronary stents: in these days of climate change should all stents wear coats? Heart 91 (Suppl. 3), iii20-iii23 (2005).
67. Su SH. Novel coating to reduce medical device encrustation. Med. Device Technol. 15(1), 12-14 (2004).
68. Watterson JD, Cadieux PA, Beiko DT et al. Oxalate-degrading enzymes from Oxalobacter formigenes: a novel device coating to reduce urinary tract biomaterial-related encrustation. J. Endourol. 17(5), 269-274 (2003).
69. Granada JF, Kaluza GL, Raizner A. Drug-eluting stents for cardiovascular disorders. Curr. Atheroscler. Rep. 5(4), 308-316 (2003).
70. Beiko DT, Watterson JD, Knudsen BE et al. Double-blind randomized controlled trial assessing the safety and efficacy of intravesical agents for ureteral stent symptoms after extracorporeal shockwave lithotripsy. J. Endourol. 18(8), 723-730 (2004).
71. Stewart MJ, Parikh S, Xiao G, Tonge PJ, Kisker C. Structural basis and mechanism of enoyl reductase inhibition by triclosan. J. Mol. Biol. 290(4), 859-865 (1999).
72. Jones GL, Russell AD, Caliskan Z, Stickler DJ. A strategy for the control of catheter blockage by crystalline Proteus mitabills biofilm using the antibacterial agent triclosan. Eur. Urol. 48(5), 838-845 (2005).
73. Cadieux PA, Chew BH, Knudsen BE et al. Triclosan loaded ureteral stents reduce Proteus mirabilis 296 infection in a rabbit UTI model. J. Urol. (2006) (an press).
74. Chew BH, Cadieux PA, Reid G, Denstedt JD. In vitro activity of triclosan loaded ureteral stents against common bacterial uropathogens. J. Endourol. 19(Suppl. 1), A10 (2005).
75. McNair AM. Using hydrogel polymers for drug delivery. Med. Device Technol. 7(10), 16-22 (1996).
76. Livnat M, Beyar R, Seliktar D. Endoluminal hydrogel films made of alginate and polyethylene glycol: physical characteristics and drug-eluting properties. J. Biomed. Mater. Res. A 75(3), 710-722 (2005).
77. Slepian MJ. Polymeric endoluminal gel paving: therapeutic hydrogel barriers and sustained drug delivery depots for local arterial wall biomanipulation. Semin. Interv. Cardiol. 1(1), 103-116 (1996).
78. Deliveliotis C, Chrisofos M, Gougousis E, Papatsoris A, Dellis A, Varkarakis IM. Is there a role for alphal-blockers in treating double-J stent-related symptoms? Urology 67(1), 35-39 (2006).